I. INTRODUCTION
The Trans-Pacific Partnership ("TPP") Agreement was signed on February 4, 2016 in Auckland, New Zealand.
1 Twelve countries, including Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States and Vietnam, were involved in this multilateral free trade agreement ("FTA"). 2 Like many FTAs, 3 the TPP Agreement has an intellectual property chapter which is Chapter 18. 4 Chapter 18 includes many provisions collectively setting a standard beyond the Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS Agreement"). 5 Article 18.53 of the TPP Agreement is a highly-criticized (Nov. 13, 2016) , http://www.theaustralian.com.au/national-affairs/foreignaffairs/transpacific-partnership-deal-not-our-only-trade-option-steve-ciobo-says/newsstory/d0fa129210d05475a9bcd15df114539b. On the other hand, Japan's intent to approve the TPP Agreement right after the U.S. presidential election makes the issue more complicate. See, e.g., Japan's Parliament Approves TPP Deal, Labeled 'Disaster' by Trump, RT, (Nov. 10, 2016), https://www.rt.com/news/366367-japan-tpp-trump-china/; Japan Lawmakers Vote to Ratify TPP, WALL STREET JOURNAL, (Nov. 4, 2016), http://www.wsj.com/articles/japanlawmakers-vote-to-ratify-tpp-1478256900. 12 The Executive Yuan is the executive branch of the Taiwan Government.
Act
13 ("PAA") on August 4, 2016. 14 The Proposed Amendment adds Chapter 4-1 governing a patent linkage system for generic drug permit ("GDP") applications. 15 The Proposed Amendment has been submitted to the Legislative Yuan. 16 The proposed patent linkage system forces a generic drug company to confront with patent law suits brought by a pioneer drug company. To do so, the Executive Yuan also introduced an amendment of the Patent Act. 17 The Patent Act Amendment provides a cause of action for a pioneer company to sue a generic drug company if the latter company files a GDP application. 18 This article is intended to explore the Proposed Amendment to figure out whether the Proposed Amendment follows Article 18.53 of the TPP Agreement or goes beyond the minimal protection on pioneer drug companies. To answer that question, it is necessary to interpret Article 18.53 to figure out the scope of protection. In this paper, Part II critically reviews Article 18.53 in light of the international law principles of treaty interpretation under Article 31(1) of the Vienna convention on the Law of Treaties ("VCLT"). Then, Part III introduces the current Pharmaceutical Affairs Act with respect to new drug applications and generic drug applications. The topics cover test data submission, patent information submission, and test data protection. Finally, Part IV analyzes the Proposed Amendment. The analysis covers the new system of patent information submission, notification mechanism, administrative action, and anti-competition. 13 It is also known as "yao-shi fa" (藥事法) in Mandarin. 
II. TPP IP CHAPTER AND PATENT LINKAGE CLAUSE
Part II discusses the prerequisite of patent linkage and analyzes three requirements of the patent linkage system under the TPP Agreement. The analysis follows Article 31(1) of the VCLT which provides that "[a] treaty shall be interpreted in good faith in accordance with the ordinary meaning to be given to the terms of the treaty in their context and in the light of its object and purpose."
19 Accordingly, the TRIPS Agreement and Declaration on TRIPS and Public Health are interpretation tools. 20 On the other hand, Article 31(2) of the VCLT further provides that "[t]he context for the purpose of the interpretation of a treaty shall comprise, in addition to the text, including its preamble and annexes: (a) any agreement relating to the treaty which was made between all the parties in connexion with the conclusion of the treaty [,] 21 but this paper does not consider those agreements made during the negotiations for the TPP Agreement because of the lack of publicly-accessible information.
A. Prerequisite of Patent Linkage
Article 18.53(1) sets only one condition as to when a member state shall provide a patent linkage system. Paragraph 1 recites:
[A] Party permits, as a condition of approving the marketing of a pharmaceutical product, persons, other than the person originally submitting the safety and efficacy information, to rely on evidence or information concerning the safety and efficacy of a product that was previously approved, such as evidence of prior marketing approval by the Party or in another territory [.] 
22
The condition has three elements. First, the marketing approval law requests an applicant to submit the safety and efficacy information of a pharmaceutical product. 23 Second, an applicant may be permitted to rely on the safety and efficacy information previously submitted by other applicant. 24 Third, the previously-submitted safety and efficacy information was used for the marketing approval of such prior applicant's product. Therefore, the patent linkage system is not required if an applicant does not rely on any previously-submitted safety and efficacy information, or if an applicant relies on the safety and efficacy information of a pharmaceutical product that is not previously approved.
The patent linkage system under the TPP Agreement must be understood in the context of data protection. Patent linkage is applied after the term of test data protection. Under Article 18.50(1), if a previously-approved product is a new pharmaceutical product, any latter applicant is not permitted to rely on the safety and efficacy information of such previously-approved product for at least five years from the date of marketing approval of such previously-approved product. Under Article 18.52, a "new pharmaceutical product" in Article 18.50(1) means "a pharmaceutical product that does not contain a chemical entity that has been previously approved."
26
The term of test data protection for at least five years also applies to a new pharmaceutical product defined in Article 18.50(2)(b) as a pharmaceutical product that contains "a chemical entity that has not previously approved [.] " 27 Under Article 18.51, the term of test data protection is at least eight years for a new pharmaceutical product "that is or contains a biologic," 28 or at least five years if other measures are also taken.
29 A "biologic" is defined in Article 18.51(2) as to include "at a minimum, a product that is, or, alternatively, contains, a protein produced using biotechnology processes, for use in human beings for the prevention, treatment, or cure of a disease or condition."
30
After the term of test data protection, a member state may permit an applicant to rely on the safety and efficacy information of a previously-approved product. At that time, such applicant is subject to the patent linkage system. Therefore, the patent linkage system functions as an extension of data protection.
It should be noted that Article 18.53(1) does not require "a product that was previously approved" to be a new pharmaceutical product as Articles 18.50 and 18.51 do. 31 But, in the context of generic drug applications, a person who originally submitted the safety and efficacy information that following generic drug companies rely on is more likely to be a right holder of the patents claiming the previouslyapproved product. This notification requirement mandates the drug approval authority of a member state to establish a mechanism to inform a patent holder of marketing approval of a product associated with her patent. But, to be an eligible patent holder, the patent in question must claim the to-be-approved product or to-be-approved treatment. 35 In other words, the patent must be a pharmaceutical formula or a treatment through use of such pharmaceutical formula. However, in a member state which excludes from patentability "diagnostic, therapeutic and surgical methods for the treatment of humans" under Article 27(3)(a) of the TRIPS Agreement, 36 an eligible patent may only be a patent claiming a pharmaceutical formula.
A patent claiming a pharmaceutical formula has a specific meaning. A pharmaceutical formula is a composition of active pharmaceutical ingredients and excipients.
37 "Excipients" include four categories: (a) substances that "aid in the processing of the drug delivery system during its manufacture"; (b) substances that "protect, support or enhance stability, bioavailability or patient acceptability"; (c) substances that "assist in product identification"; (d) substances that "enhance any other attribute of the overall safety, effectiveness or delivery of the drug during storage or use."
38 Thus, for purposes of patent linkage, an eligible drug patent must claim not only active pharmaceutical ingredients and excipients of the previously-approved drug, but also dosage forms thereof. 
Timing Requirement
The second requirement is the timing requirement. Article 18.53(1)(b) mandates a member state to provide "adequate time and opportunity for such a patent holder to seek, prior to the marketing of an allegedly infringing product, available remedies in subparagraph (c) [.] " 40 Three aspects may be added to the interpretation of Article 18.53(1)(b). First, the use of "seek" indicates that only a right to seek subparagraph (c) remedies is required, but actual granting of such remedies in every case is not mandatory. Second, the phrase "prior to the marketing of an allegedly infringing product" indicates that a right to seek available remedies in subparagraph (c) may be provided before the authority grants marketing approval or between the issue of marketing approval and actual marketing by the approval holder. That is, it is not required to stay the proceeding of marketing approval review before the patentee seeks mandatory remedies. Third, the "adequate time and opportunity" factor must be considered. Thus, it may not be adequate to avail the right to seek the required remedies just before the approval holder starts to market the allegedly infringing product.
"Procedure and Remedy" Requirement
The last requirement is the "procedure and remedy" requirement. Article 18.53(1)(c) demands "procedures, such as judicial or administrative proceedings, and expeditious remedies, such as preliminary injunctions or equivalent effective provisional measures, for the timely resolution of disputes concerning the validity or infringement of an applicable patent claiming an approved pharmaceutical product or its approved method of use."
41 That is, a member state must provide judicial or administrative proceedings. In those proceedings, an eligible patentee may move for either preliminary injunctions or equivalent effective provisional measures. The proceedings must be timely to resolve the issue of validity or infringement. However, a few questions remain.
The first question is whether there exists any infringing act during the marketing approval proceeding. If there is no infringing act, the only dispute will be validity. The interpretation of Article 18.53(1)(c) should not go that way. Otherwise, the term "infringement" would be void, which unlikely reflects the intent of the TPP Agreement. Thus, it is necessary to figure out which act is an infringing act during the marketing approval proceeding.
Under Article 28(1)(a) of the TRIPS Agreement, a patentee has exclusive rights to prevent others from making, using, offering for sale, selling, or importing for these purposes, her patented product. 42 Or, under Article 28(1)(b) of the TRIPS Agreement, a holder of a process patent has a right to exclude others from using her patented 40 TPP Agreement art. 18.53(1)(b) (emphasis added).
41 TPP Agreement art. 18.53(1)(c). 42 See TRIPS Agreement art. 28(1)(a) ("A patent shall confer on its owner the following exclusive rights: (a) where the subject matter of a patent is a product, to prevent third parties not having the owner's consent from the acts of: making, using, offering for sale, selling, or importing for these purposes that product[.]").
process. 43 Because the TPP Agreement does not create any new exclusive rights, the rights of an eligible patent holder under the TPP Agreement are limited to Article 28(1) of the TRIPS Agreement. In addition, seeking a marketing approval may not be an act of infringement under Article 18.49 of the TPP Agreement. 44 Therefore, the question becomes whether acquiring a marketing approval constitutes infringement.
A marketing approval holder has a right to market his approved drug. But, that is not equal to infringement. Marketing may mean advertising, events, knocking on doors, or direct mail. 45 In any case, a drug company markets its product because it wants to sell the product to targeted customers, such as doctors, hospitals, pharmacists, and patients. If a drug company merely promotes the availability of its product, there may be no infringement. But, if prices are in the marketing materials, such marketing act is more likely to constitute an "offer for sale" so as to infringe the patent. 46 It is evident that a marketing approval holder will eventually offer a price of its drug to potential buyers. As a result, there is a potential threat to the patent holder. A timely resolution of the infringement issue is required when a marketing approval is granted. The issue of validity must be accompanied. Without a valid patent, there will be no infringement.
The second question is what "timely resolution" means. Although the TPP Agreement does not provide any clue, the phrase may be understood in light of Article 42 of the TRIPS Agreement. Article 42 requires that " [d] efendants shall have the right to written notice which is timely and contains sufficient detail, including the basis of the claims." 47 Article 42 also provides that all parties "shall be duly entitled to substantiate their claims and to present all relevant evidence."
48 Therefore, the implementation of "timely resolution" should consider not only the interests of a patent holder, but also a marketing approval holder's right of due process.
The last question is the scope of "expeditious remedies." Article 18.53(1)(c) specifies "preliminary injunctions or equivalent effective provisional measures" as two categories of expeditious remedies. The use of "preliminary" and "provisional" indicates that those injunctions or measures are imposed before a court issues a final decision regarding whether the patent is infringed or whether the patent is valid. But, 43 See TRIPS Agreement art. 28(1)(b) ("A patent shall confer on its owner the following exclusive rights: … (b) where the subject matter of a patent is a process, to prevent third parties not having the owner's consent from the act of using the process, and from the acts of: using, offering for sale, selling, or importing for these purposes at least the product obtained directly by that process."). 44 See TPP Agreement art. 18.49 ("Without prejudice to the scope of, and consistent with, Article 18.40 (Exceptions), each Party shall adopt or maintain a regulatory review exception for pharmaceutical products."). 45 See JOHN BURNETT, CORE CONCEPTS OF MARKETING 3 (2008), available at http://www.saylor.org/site/wp-content/uploads/2012/11/Core-Concepts-of-Marketing.pdf (last visited Oct. 16, 2016). 46 See 3D Sys., Inc. v. Aarotech Labs., Inc., 160 F.3d 1373, 1379 (1998) ("As a matter of federal statutory construction, the price quotation letters can be regarded as 'offer[s] to sell' under § 271 based on the substance conveyed in the letters, i.e., a description of the allegedly infringing merchandise and the price at which it can be purchased." (alterations in original)).
47 TRIPS Agreement art. 42. 48 Id.
whether those expeditious remedies are mandatory is unclear. What factor has to be included in the consideration of those expeditious remedies is not listed in Article 18.53.
The availability of "expeditious remedies" may be determined in view of Article 18.50(3) of the TPP Agreement. Article 18.50(3) provides that a member state "may take measures to protect public health in accordance with: (a) the Declaration on TRIPS and Public Health [.] " 49 Although the Doha Declaration on TRIPS and Public Health (hereinafter, "Doha Declaration") focuses on the issue of compulsory licensing, 50 it emphases a balance between the importance of intellectual property protection for new drug development and the concerns on drug prices.
51 Thus, public interests should be taken into consideration when expeditious remedies are implemented. This norm is also adopted in the United States as the Federal Circuit has held that "[t]o obtain a preliminary injunction, a party must show 'that it is likely to succeed on the merits, that it is likely to suffer irreparable harm in the absence of preliminary relief, that the balance of equities tips in its favor, and that an injunction is in the public interest. '" 52 In conclusion, the "procedure and remedy" requirement mandates procedures and expeditious remedies for a patent holder to resolve the issue of valid or infringement of her patent claiming the approved drug when the marketing approval is granted. But, the procedures must balance the interests of the patent holder and marketing approval holder. Public health must also be considered.
C. Alternative to the Patent Linkage System
Article 18.53(2) of the TPP Agreement establishes an alternative system to the patent linkage system under Article 18.53(1). Article 18.53(2) provides:
As an alternative to paragraph 1, a Party shall instead adopt or maintain a system other than judicial proceedings that precludes, based upon patentrelated information submitted to the marketing approval authority by a patent holder or the applicant for marketing approval, or based on direct coordination between the marketing approval authority and the patent office, the issuance of marketing approval to any third person seeking to market a pharmaceutical product subject to a patent claiming that product, unless by consent or acquiescence of the patent holder. The phrase "an alternative to paragraph 1" indicates that a system under Article 18.53(2) is not mandatory but optional. The system is defined as a non-judicial proceeding, so it has to be an administrative proceeding. By stating that a drug authority "precludes, … , the issuance of marketing approval," Article 18.53(2) does not require the authority to deny or reject the application for marketing approval. "Preclude" means "to make (something) impossible," "to prevent (something) from happening," or "to prevent (someone) from doing something." 54 Thus, Article 18.53(2) may merely require a stay of issuing a marketing approval.
Under Article 18.53(2), preclusion of the issuance of marketing approval may be based on the "patent-related information" submitted by a patent holder or marketing approval applicant. But, the definition of "patent-related information" is unclear. It may mean at least the information of patents as required in Article 18.53(1). In addition, preclusion may be based on "direct coordination" between the drug authority and patent authority. The second basis is more ambiguous because the TPP Agreement does not give any instruction on how two authorities may work together to conclude a decision of preclusion. Therefore, it is more difficult to implement Article 18.53(2) than Article 18.53(1).
It should be noted that by providing a system for a drug authority to preclude the issuance of marketing approval, Article 18.53(2) reaffirms that the timing for initiating the patent linkage system under Article 18.53(1) is the time of issuing a marketing approval. Otherwise, Article 18.53(2) is not distinct enough as to be an alternative to Article 18.53(1).
D. Summary
While the exact meaning of the "patent linkage" provision under the TPP Agreement is uncertain, the above analysis may provide some insights of how to implement the provision as follows:
(1) A patent linkage system is required only when an applicant for marketing approval relies on the safety and efficacy information of a previously-approved drug.
(2) To enjoy the benefits of patent linkage, an eligible patent holder must own a patent claiming a pharmaceutical formulation or method for using such pharmaceutical formulation. But, in a member state adopting Article 27(3)(a) of the TRIPS Agreement, only a person who holds a patent for a pharmaceutical formulation is eligible.
(3) A patent holder must be informed of the marketing approval of a drug covered by her eligible patent when the drug authority issues the approval.
(4) A procedure for the timely resolution of infringement or validity of the patentin-suit may be an administrative or judicial procedure. While the interests of a patentee are primarily concerned with, the procedure must consider a marketing approval holder's right of due process.
(5) A right to seek expeditious remedies, such as preliminary injunctions or equivalent effective provisional measures, is required. But, the grant of such remedies must consider public health issues.
(6) An alternative administrative procedure may be provided where the drug authority may preclude the issuance of marketing approval. Preclusion may be based on the patent-related information submitted by either a patent holder or marketing approval holder. The coordination between the drug authority and patent authority may also be a basis for preclusion.
III. DRUG PERMIT APPLICATION UNDER THE PHARMACEUTICAL AFFAIRS ACT

A. Drug Permit
The Pharmaceutical Affairs Act ("PAA") is a multi-task law governing drugs, medical devices, pharmaceutical companies, pharmacies and other relevant matters. 55 The PAA is administrated by the Food and Drug Administration (hereinafter, "Taiwan FDA"). 56 Chapter 4 of the PAA regulates the proceedings of registration and market approval of medicaments. Article 39 specifically provides the proceeding of approval of a "drug permit" (藥品許可證, yao-pin xu-ke zheng; hereinafter, "DP"). 57 Paragraph 4 of Article 39 authorizes the Ministry of Health and Welfare to promulgate the Regulations for Registration of Medicinal Products 58 ("Regulations") to review a DP. 59 Without a DP, a company cannot manufacture or import drugs. 60 An unlicensed 55 See PAA art. 1, para. 2 ("The term 'pharmaceutical affairs' used in the preceding Paragraph shall refer to medicaments, pharmaceutical firms, pharmacies and other relevant matters."); art. 4 ("The term 'medicaments' as used in this Act shall refer to drugs and medical devices."). 56 See About FDA, Food and Drug Administration, Ministry of Health and Wealth (June 6, 2006) http://www.fda.gov.tw/EN/aboutFDAContent.aspx?id=17&chk=ec07b726-f665-4825-ba5a-7d2387a299ad (last visited Oct. 16, 2016). 57 See PAA art. 39, para. 1 (" For the manufacturing and import of drugs, information concerning the ingredients, source of active pharmaceutical ingredients, specifications, functions, summary of manufacturing process, and the specification and method of testing, as well as other related information and certificates, accompanied by labels and use instructions in the original and Chinese languages, and samples, together with the fee paid, shall be filed with the central competent health authority for registration and market approval. No manufacturing or importation of such drugs shall be allowed until a drug permit license is approved and issued."). 58 It is also known as "yao-pin cha-yan deng-ji shen-cha zhun-ze" (藥品查驗登記審查準 則) in Mandarin. 59 See PAA art. 39, para. 4 ("The application criteria, review procedure, approval criteria, and other matters to be complied with shall be established in the Regulations for Registration of Medicinal Products by the central competent health authority."). 60 See Id. at ⁋ 1. drug is considered a fake or counterfeit drug. 61 A person who manufactures, imports, or sells unlicensed drugs is criminally liable. 62 A "new drug" is defined in Article 7 of the PAA as "a drug which can be recognized through the examination of the central healthcare authority as a new compound, composition with a new therapeutic effect, or dosage form with a new administration." 63 Article 38-1 of the Regulations requires a "new drug permit" ("NDP") applicant for a new compound to submit test data of either of two categories. 64 The first-category data comes from Phase I conducted during the research period in Taiwan and Phase III simultaneously conducted in a foreign country. 65 The second-category data comes from Phase II and Phase III conducted simultaneously in Taiwan and foreign country. 66 The Regulations also provide the experimental requirements for Phases I, II, and III. 67 Phase I is considered experimental in its nature and requires a pharmacokinetics study or pharmacodynamics study. 68 In both studies, the number of tested people is at least ten in principle. 69 Phase II is clinical testing where the number of tested people is at least twenty in principle. 70 Phase III is known as a pivotal trial where the number of tested people is at least eighty in principle so as to sufficiently show that the test result in Taiwan is similar to that in the foreign country. 71 The testing conditions of Phases I, II, or III may be modified by the Taiwan FDA. 72 Tested people must be selected from Taiwanese people. Alternatively, Article 38-2 of the Regulations allows an applicant to rely on drug approval issued by Germany, United States, United Kingdom, France, Japan, Switzerland, Canada, Australia, Belgium, or Sweden. 73 But, the applicant is still required to submit clinical testing data of Phases I, II, and III. 74 Phase I under Article 38-2 is the same as Phase I under Article 38-1. 75 Phases II & III under Article 38-2 should be conducted in medical centers of multiple countries, but the number of tested Taiwanese people must meet either of two conditions. 76 The first condition requires that the number for Phase II is at least twenty in principle and that number for Phase III is at least eighty in principle. 77 The second condition requires in both Phase II and Phase III, the number of tested Taiwanese people should amount to at least ten percent of the total tested people around the different medical centers.
78
In addition, Article 38-2 of the Regulations requires a second type of Phase III clinical data.
79 While the second type should be conducted in medical centers of multiple countries, the countries must include one of Germany, United States, United Kingdom, France, Japan, Switzerland, Canada, Australia, Belgium, and Sweden. 80 If the number of total tested people is above or equal to two hundreds, the number of Taiwanese tested people should be at least thirty in principle or amount to at least five percent of the total tested people. 81 If the number of total tested people is below two hundreds, the number of Taiwanese tested people should be at least ten in principle.
82
The testing conditions may be modified by the Taiwan FDA. 83 Finally, the test report for the second type must have been submitted to the Food and Drug Administration of the United States and European Medicines Agency of the European Union as a reference for drug approval.
84
Under Article 38-3, the testing data required by either Article 38-1 or Article 38-2 may be waived by the Taiwan FDA.
85 But, the authority may require the submission of bridging study data. 86 Currently, the examination of a drug permit application is not actually performed by the Taiwan FDA. Instead, the Taiwan FDA has delegated its power of examination to a non-governmental organization, the Center for Drug Evaluation ("CDE"). 87 The Taiwan FDA is an office receiving submissions, while the CDE examines the scientific validity of those submissions.
C. Disclosure of Patent Information
The disclosure of patents or patent applications related to an approved new drug is not mandatory under the PAA, while Article 40-2, Paragraph 1 requires the Taiwan FDA to publish publicly-disclosed patent numbers or patent application numbers submitted by a NDP applicant. 88 Because the Taiwan FDA is required to publish the patent information of an approved drug, the Taiwan FDA has promulgated "an affidavit form of previously-disclosed patent numbers or patent application numbers" (已揭露專利字號/案號切結書, yi jie-lu zhuan-li zi-hao or an-hao qie-jie shu). 89 In principle, a NDP applicant has to file such form when submitting her application for drug approval. However, not all applicants follow the Taiwan FDA's instruction.
90
D. Test Data Protection
Article 40-2 of the PAA provides the protection on test data submitted by previous NDP applicants for a new compound. 91 If the NDP holder of a previously-approved new compound has a marketing approval for the same compound in a foreign country, to enjoy the data protection, she must file a NDP application in three years from the issuance of her foreign marketing approval.
92 Article 40-2, Paragraph 2 prevents a latter applicant from relying on the test data of a previously-approved new compound for five years from the issuance of the drug permit for such new compound. 93 However, Article 40-2, Paragraph 3 allows a drug permit application for a drug that has the same compound, same dosage form, same dosage, and same unit dose as a previously-approved drug has possessed.
94 But, such Paragraph 3 application is permitted only after three years from the issuance of the NDP of such previouslyapproved new compound. 95 Article 40-2, Paragraph 2 still applies to when a Paragraph 3 application may rely on the test data of a previously-approved new compound. 
E. "Generic Drug Permit" Application
Although the PAA does not define a "generic drug," the Regulations do define a "generic drug" as a drug that has the same compound, same dosage form, same dosage, and same efficacy of a previously-approved drug. 97 Therefore, in Article 40-2, Paragraph 3 of the PAA, a drug that has the same compound, same dosage form, same dosage, and same unit dose as a previously-approved drug may be considered as a generic version of such previously-approved drug. 98 A Paragraph 3 application is a Taiwanese version of a generic drug application.
However, the PAA does not allow a GDP applicant to rely on her own test data. The Proposed Amendment does not change that. As analyzed in Part II, the prerequisite of the patent linkage system under Article 18.53 is that a GDP applicant relies on previously-submitted test data. 99 If a GDP applicant chooses to submit his own test data, he is not subject to the patent linkage system. 100 Therefore, the PAA and Proposed Amendment are not flexible to a generic drug company.
IV. TAIWAN'S PROPOSED PATENT LINKAGE SYSTEM
The TPP Agreement requires a member state either to adopt a notification mechanism under Article 18.53(1) or to stay the issuance of marketing approval under Article 18.53(2).
101 But, Taiwan's implementation of Article 18.53 includes a notification mechanism and allows the health authority to stay the issuance of a GDP. 102 Whether the health authority may lift the stay depends on whether the patent dispute surrounding a GDP application is resolved in favor of the GDP applicant. 
A. Patent Information Submission
The proposed patent linkage system starts with the provisions concerning "patentrelated information" mentioned in Article 18.53(2) of the TPP Agreement.
104 Article 48-3 and Article 48-5 of the Proposed Amendment condition whether one may benefit from patent linkage on whether she timely submits patent information related to her NDP.
105 Article 48-3, Paragraph 1 provides that "if a drug permit holder of a new drug thinks that it is necessary to submit the patent information of drug patents, she should prepare relevant documents and information and submit them to the central health 97 See Regulations for Registration of Medicinal Products Art. 4 (2015). 98 PAA Art. 40-2, ¶ 3. 99 See id. 100 See id. 101 See TPP Agreement art. 18.53. 102 Id. 103 Id. 104 
Id.
105 PAA Arts. 48-3, 48-5. authority, the (c) information of the exclusive licensee is required. 119 If the owner or exclusive licensee of a drug patent does not reside, domicile, or have a business place in Taiwan, the (c) information of her agent is required.
120 Last, if a NDP holder is not the owner or exclusive licensee of the drug patent, when submitting the required patent information, she should acquire a consent from the owner or exclusive licensee.
121
The required patent information of a drug patent may be corrected by a NDP holder. 122 Under Article 48-6, a NDP holder should apply for an amendment of patent information if any of the following conditions have occurred: (a) the patent authority grants and announces the extension of the term of protection; (b) the claims have been amended and published; (c) the revocation of the drug patent has been finalized; (d) the drug patent has expired; (e) the information of the patent owner, exclusive licensee, or agent has changed.
123 If a NDP holder is not the owner or exclusive licensee of a drug patent, such amendment should be permitted by the patentee or exclusive licensee. 124 Furthermore, a NDP holder is required to file an amendment in forty-five days from the next day of the occurrence of any of those five conditions. 125 But, there is no negative consequence if she fails to do so.
The public may challenge the correctness of the required patent information.
126
Article 48-7 provides that any person may notify the Taiwan FDA of any of the following incidents: (a) the documented drug patent has nothing to do with the approved drug; (b) the documented drug patent does not claim a material, combination or formula, or pharmaceutical use; (c) errors exist in the patent information; (d) the NDP holder fails to comply with Article 48-6. 127 Such person should submit written reasons and evidence to support an Article 48-7 notification. 128 Then, the Taiwan FDA should forward the notification to the NDP holder in twenty days from the next day of the filing of the notification. 129 Next, the NDP holder should respond to the Taiwan FDA with written reasons, but the NDP holder is free to decide whether to file an amendment. 130 In the end, the Taiwan FDA is not required to change the challenged information even if it is incorrect. 131 Instead, the Taiwan FDA is only mandated to complete. 143 If the submitted data meets the requirements, the Taiwan FDA will serve a notification of completeness of data submission to the GDP applicant. 144 When a declaration of the fourth situation is made, Article 48-12 requires a GDP applicant to serve a written notification to the NDP holder and Taiwan FDA in twenty days starting from the next day of the GDP applicant's receipt of the completeness notification. 145 If the NDP holder does not own the patent or is not licensed exclusively, an Article 48-12 notification must also be served on the patentee or exclusive licensee. 146 The written notification must include reasons and evidence of invalidity or non-infringement. 147 If the GDP applicant fails to timely serve an Article 48-12 notification, the Taiwan FDA will reject the GDP application. 148 As analyzed in Part II, the proper timing for a notification under Article 18.53(1) is the health authority's granting of marketing approval. 149 But, the Taiwan's approach requires a notification to be delivered by a GDP applicant to a patentee or exclusive licensee when the GDP application is filed. 150 The GDP applicant is also required to show why the patent at dispute is invalid or not infringed. 151 That is, the burden of proof is imposed on the GDP applicant who is a potential patent infringer.
C. Stay of Issuance of a Drug Permit to a GDP Applicant
The Proposed Amendment introduces a mechanism where the Taiwan FDA may stay issuance of a drug permit to a GDP applicant. Under Article 48-13, the mechanism is controlled by the patentee or exclusive licensee. 152 After the patentee or exclusive licensee receives an Article 48-12 notification, he must sue the GDP applicant for infringement of any documented patents in forty-five days starting from the next day of the receipt of the Article 48-12 notification. 153 Article 48-13 further provides that the period of forty-five days runs from the receipt by the patentee or exclusive licensee, whoever receives the Article 48-12 notification later. 154 The patentee or exclusive licensee must notify the Taiwan FDA of the filing of such law suit. 155 receipt of the Article 48-12 notification. 156 But, the Taiwan FDA may issue a drug permit to the GDP applicant in any of the following situations 157 : (1) The patentee or exclusive licensee does not initiate a law suit during the required period of forty-five days.
(2) The law suit filed after the receipt of the Article 48-12 notification is not based on a patent documented under Article 48-3, 48-5, or 48-21 before the GDP application.
(3) Courts find that all patents disputed in the law suit should have been invalidated, or the GDP applicant wins a decision of non-infringement.
(4) All patents stated in the declaration of a fourth situation under Article 48-9 have been revoked by the Taiwan Intellectual Property Office.
(5) The patentee (or exclusive licensee) and GDP applicant have agreed to settle the dispute.
(6) All patents stated in the declaration of a fourth situation under Article 48-9 have expired.
If the patentee or exclusive licensee wins the law suit filed under Article 48-13 and if the winning decision is finalized in fifteen months starting from the next day of the NDP holder's receipt of the Article 48-12 notification, the Taiwan FDA is obligated under Article 48-13 not to issue a GDP until the patent at dispute expires. 158 But, a stay under Article 48-13 is only implemented once. 159 If the patent or exclusive licensee sues the same GDP applicant for the same generic drug again with a different documented patent not brought in the previous law suit, the Taiwan FDA will not stay issuance of a GDP. 160 Last, while the Taiwan FDA must stay issuance of a GDP, it can continue the examination of the GDP application. 161 Under Article 48-15, if the Taiwan FDA completes the examination, it should notify the GDP applicant. 162 After receiving an Article 48-15 notification, the GDP applicant may file to the National Health Insurance Administration an application for inclusion of her drug product in the national health insurance system and for price determination 163 But, the GDP applicant is not allowed to manufacture or import the generic drug until a GDP is issued. 164 
D. Exclusive Sales Period
The Proposed Amendment grants a period of exclusive sales to a GDP applicant who has made a declaration of the fourth situation under Article 48-9, if such applicant eventually gets a GDP. 165 During the exclusive sales period, the Taiwan FDA is prevented from granting other GDPs for the same drug. 166 But, it should be noted that under Article 48-20 a right of exclusive sales applies only if the drug under a GDP was a drug of a new compound. 167 If the drug was a drug of a composition with a new therapeutic effect or a drug of a dosage form with a new administration, a right of exclusive sales does not exist. 168 Under Article 48-16, a GDP holder whose data submission has been first considered complete by the Taiwan FDA will earn an exclusive sales period of twelve months. 169 However, the calculation of the period does not start from the receipt of a GDP. Under Article 48-17, the period starts from actual sale of the products under such GDP. 170 The exclusive GDP holder has to report the actual sale to the Taiwan FDA in twenty days starting from the next day of the actual sale. 171 Then, the Taiwan FDA will determine the period including the starting date and expiration date. 172 However, in the context of multiple GDP applicants, Article 48-16 provides that if the Taiwan FDA determines that more than one GDP applicants complete their data submission on the same day, these GDP applicants will share an exclusive sales period. 173 In addition, the calculation of the period starts from the earliest actual sale made by any of those GDP applicants. 174 A GDP applicant who is supposed to enjoy an exclusive sales period may lose his right to exclusive sales, if any of the following three situations occurs with respect to his GDP application 175 
:
(1) During the examination of the GDP application, the declaration a fourth situation under Article 48-9 has been withdrawn.
(2) A notification of the completion of the examination is not received in twelve months starting from the next day of the completeness of the data submission.
(3) The patentee or exclusive licensee wins the law suit filed under Article 48-13, and the winning decision is finalized in fifteen months starting from the next day of the NDP holder's receipt of the Article 48-12 notification.
If the first GDP applicant loses a right to exclusive sales, other following GPD applicants for the same drug may earn such right. 176 Article 48-16 provides that the determination of which following GPD applicant inherits such right depends on the likely to violate the Fair Trade Act, it will refer the case to the Fair Trade Commission for further proceedings.
V. CONCLUSION
To prepare for joining the TPP Agreement, the Taiwan Government has begun to implement a patent linkage system required under Article 18.53 of the TPP Agreement. Taiwan' approach is a pro-patentee mechanism. The mechanism allows a NDP holder to register patents claiming (a) a material; (b) a combination or formula; or (c) pharmaceutical use. 190 The scope of patentees who may benefit from the mechanism is larger than what Article 18.53 requires. In addition, the mechanism requires a GDP applicant to notify the NDP holder and patentee at the time of filing the GDP application when the applicant asserts no patents associated with the generic drug are valid or infringed. 191 The mechanism forces the GDP applicant to prove invalidity or non-infringement. 192 Furthermore, the mechanism allows the Taiwan FDA to stay the issuance of a GDP while the patentee is suing the GDP applicant in the court.
193 Therefore, the proposed patent linkage system may be considered as TPPPlus. 189 See PAA Art. 48-19, ¶ 3.
190 TPP Agreement art. 18.53. 191 Id. 192 Id. 193 Id.
